Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors

Estrella Lopez-Gordo, Iva I. Podgorski, Nicholas Downes, Ramon Alemany

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase their safety profile, there are still pitfalls that need to be further addressed. Preexisting humoral and cellular immunity against common HAdV serotypes limits the efficacy of gene transfer and duration of transgene expression. As an alternative, nonhuman AdV (NHAdV) vectors can circumvent neutralizing antibodies against HAdVs in immunized mice and monkeys and in human sera, suggesting that NHAdV vectors could circumvent preexisting humoral immunity against HAdVs in a clinical setting. Consequently, there has been an increased interest in developing NHAdV vectors for gene delivery in humans. In this review, we outline the recent advances and limitations of HAdV vectors for gene therapy and describe examples of NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective gene therapy vehicles.

Original languageEnglish
Pages (from-to)285-300
Number of pages16
JournalHuman Gene Therapy
Issue number4
StatePublished - 1 Apr 2014
Externally publishedYes


Dive into the research topics of 'Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors'. Together they form a unique fingerprint.

Cite this